Literature DB >> 23635963

Phenotypic heterogeneity of the 8344A>G mtDNA "MERRF" mutation.

Michelangelo Mancuso1, Daniele Orsucci, Corrado Angelini, Enrico Bertini, Valerio Carelli, Giacomo Pietro Comi, Carlo Minetti, Maurizio Moggio, Tiziana Mongini, Serenella Servidei, Paola Tonin, Antonio Toscano, Graziella Uziel, Claudio Bruno, Elena Caldarazzo Ienco, Massimiliano Filosto, Costanza Lamperti, Diego Martinelli, Isabella Moroni, Olimpia Musumeci, Elena Pegoraro, Dario Ronchi, Filippo Maria Santorelli, Donato Sauchelli, Mauro Scarpelli, Monica Sciacco, Marco Spinazzi, Maria Lucia Valentino, Liliana Vercelli, Massimo Zeviani, Gabriele Siciliano.   

Abstract

OBJECTIVES: Myoclonic epilepsy with ragged-red fibers (MERRF) is a rare mitochondrial syndrome, mostly caused by the 8344A>G mitochondrial DNA mutation. Most of the previous studies have been based on single case/family reports or series with few patients. The primary aim of this study was the characterization of a large cohort of patients with the 8344A>G mutation. The secondary aim was revision of the previously published data.
METHODS: Retrospective, database-based study (Nation-wide Italian Collaborative Network of Mitochondrial Diseases) and systematic revision.
RESULTS: Forty-two patients carrying the mutation were identified. The great majority did not have full-blown MERRF syndrome. Myoclonus was present in 1 of 5 patients, whereas myopathic signs and symptoms, generalized seizures, hearing loss, eyelid ptosis, and multiple lipomatosis represented the most common clinical features. Some asymptomatic mutation carriers have also been observed. Myoclonus was more strictly associated with ataxia than generalized seizures in adult 8344A>G subjects. Considering all of the 321 patients so far available, including our dataset and previously published cases, at the mean age of approximately 35 years, the clinical picture was characterized by the following signs/symptoms, in descending order: myoclonus, muscle weakness, ataxia (35%-45% of patients); generalized seizures, hearing loss (25%-34.9%); cognitive impairment, multiple lipomatosis, neuropathy, exercise intolerance (15%-24.9%); and increased creatine kinase levels, ptosis/ophthalmoparesis, optic atrophy, cardiomyopathy, muscle wasting, respiratory impairment, diabetes, muscle pain, tremor, migraine (5%-14.9%).
CONCLUSIONS: Our results showed higher clinical heterogeneity than commonly thought. Moreover, MERRF could be better defined as a myoclonic ataxia rather than a myoclonic epilepsy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23635963     DOI: 10.1212/WNL.0b013e318294b44c

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  56 in total

1.  Lactose-free diet inducing aseptic pancreatitis and myoclonic jerks in late-onset, putative MERRF syndrome.

Authors:  Josef Finsterer; Werner Habitzl
Journal:  J Neurol       Date:  2016-01-25       Impact factor: 4.849

2.  Beyond cervical lipomas: myoclonus, gait disorder and multisystem involvement leading to mitochondrial disease.

Authors:  Roberto López-Blanco; Ana Rojo-Sebastián; Maria Henedina Torregrosa-Martínez; Alberto Blazquez
Journal:  BMJ Case Rep       Date:  2017-06-19

Review 3.  Mitochondrial DNA heteroplasmy in disease and targeted nuclease-based therapeutic approaches.

Authors:  Nadee Nissanka; Carlos T Moraes
Journal:  EMBO Rep       Date:  2020-02-19       Impact factor: 8.807

4.  Madelung disease in a 58-year-old man.

Authors:  Shigehiro Karashima; Takashi Yoneda
Journal:  CMAJ       Date:  2019-01-14       Impact factor: 8.262

Review 5.  Control of mitochondrial integrity in ageing and disease.

Authors:  Radek Szklarczyk; Marco Nooteboom; Heinz D Osiewacz
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-07-05       Impact factor: 6.237

6.  Revisiting mitochondrial ocular myopathies: a study from the Italian Network.

Authors:  D Orsucci; C Angelini; E Bertini; V Carelli; G P Comi; A Federico; C Minetti; M Moggio; T Mongini; F M Santorelli; S Servidei; P Tonin; A Ardissone; L Bello; C Bruno; E Caldarazzo Ienco; D Diodato; M Filosto; C Lamperti; I Moroni; O Musumeci; E Pegoraro; G Primiano; D Ronchi; A Rubegni; S Salvatore; M Sciacco; M L Valentino; L Vercelli; A Toscano; M Zeviani; G Siciliano; M Mancuso
Journal:  J Neurol       Date:  2017-07-10       Impact factor: 4.849

Review 7.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

8.  Overexpression of mitochondrial histidyl-tRNA synthetase restores mitochondrial dysfunction caused by a deafness-associated tRNAHis mutation.

Authors:  Shasha Gong; Xiaoqiong Wang; Feilong Meng; Limei Cui; Qiuzi Yi; Qiong Zhao; Xiaohui Cang; Zhiyi Cai; Jun Qin Mo; Yong Liang; Min-Xin Guan
Journal:  J Biol Chem       Date:  2019-12-09       Impact factor: 5.157

9.  Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation: data from the German mitoNET registry.

Authors:  Judith Altmann; Boriana Büchner; Aleksandra Nadaj-Pakleza; Jochen Schäfer; Sandra Jackson; Diana Lehmann; Marcus Deschauer; Robert Kopajtich; Ronald Lautenschläger; Klaus A Kuhn; Kathrin Karle; Ludger Schöls; Jörg B Schulz; Joachim Weis; Holger Prokisch; Cornelia Kornblum; Kristl G Claeys; Thomas Klopstock
Journal:  J Neurol       Date:  2016-03-19       Impact factor: 4.849

Review 10.  Overview of Atypical Diabetes.

Authors:  Jaclyn Tamaroff; Marissa Kilberg; Sara E Pinney; Shana McCormack
Journal:  Endocrinol Metab Clin North Am       Date:  2020-10-14       Impact factor: 4.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.